iBio, Inc. IBIO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
iBio, Inc. (IBIO) is a healthcare company listed in the US with a market value of about $52M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$35M, a net margin of -3244.2%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -47% a year, a 5-year average ROIC of -58%.
About iBio
iBio is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $948000 in 2016 to $100000 in 2026, a decline of about 20.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 16903% over three years (dilution for shareholders). It spends 19643% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $100000 | $400000 | $225000 | $0 | $2M | $2M | $2M | $2M | $444000 | $394000 |
| Net income | -$35M | -$33M | -$18M | -$25M | -$65M | -$50M | -$23M | -$16M | -$18M | -$16M | -$15M |
| Free cash flow | -$28M | -$24M | -$15M | -$19M | -$36M | -$45M | -$35M | -$14M | -$15M | -$14M | -$14M |
| EPS (diluted) | $-0.47 | $-0.32 | $-1.75 | $-6.50 | $-106.19 | $-115.65 | $-60.02 | $-12.20 | $-18.81 | $-30.81 | $-32.81 |
| Net margin | -3244.2% | -33044.0% | -4594.2% | -11069.8% | — | -2670.0% | -978.8% | -1003.6% | -871.8% | -3627.2% | -3688.3% |
| ROIC | — | -40.0% | -101.5% | -51.7% | -72.3% | -26.3% | -22.5% | -19.3% | -506.4% | -69.5% | -126.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does iBio pay a dividend?
Not currently.
Is iBio a good stock to buy?
We do not give buy or sell advice. iBio scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.